Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from the Bayer HealthCare Phase 3 CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial of Bayer's investigational compound regorafenib (BAY 73-4506). The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 months for the placebo group) in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies.[i] This late-breaking abstract, with these updated data, will be presented by Axel Grothey, MD, Professor of Oncology, Mayo Clinic and co-principal investigator of the CORRECT study, in an oral abstract session (LBA No. 385, January 21, 2012 from 2:30 p.m. – 4:00 p.m. PT, Level 3 Ballroom, Moscone Center West) at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.

Additionally, findings from the secondary endpoints of the CORRECT study showed statistically significant improvement in progression-free survival (PFS) (HR=0.49, p<0.000001, median PFS: 1.9 months vs. 1.7 months) and an improvement in disease control rate (44.8% vs. 15.3%) in patients treated with regorafenib compared to those treated with placebo. The difference in objective response rate between the two arms (1.0% vs. 0.4%) did not reach statistical significance.[i]

The most common drug-related treatment-emergent adverse events included fatigue (47.4% vs. 28.1%), hand-foot skin reaction (46.6% vs. 7.5%), diarrhea (33.8% vs. 8.3%), anorexia (30.4% vs. 15.4%), hypertension (27.8% vs. 5.9%), oral mucositis (27.2% vs. 3.6%) and rash/desquamation (26.0% vs. 4.0%) for patients receiving regorafenib
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... signed an exclusive, global license agreement with Plasma ... of its proprietary plasma fractionation process. Concurrently, the ... its intention to strategically refocus and rebrand the ... to pursue a national listing for its common ...
(Date:9/22/2014)... cancer is the second leading cause of cancer death ... early - the problem is that too often it ... Education Council (PCEC), – a national organization committed ... screening –  is sponsoring its 25 th Annual ... Committed to encouraging men to take a ...
(Date:9/22/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a ... announced that study designs and progress from two of ... global Phase 3 clinical trial in relapsed/refractory soft tissue ... in small cell lung cancer, will be presented at ... being held September 26-30, in Madrid, Spain ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
(Date:9/22/2014)... Tara Haelle HealthDay ... -- Measuring how quickly a child,s brain processes sounds ... a new study. Observing children,s brainwaves may ... possible, the study authors reported. "The finding that ... associated with autism severity is hugely promising," said senior ...
(Date:9/22/2014)... “The Race is On!” for the 22nd Susan G. ... 2014 as it moves to its new location at Cesar ... fundraising and awareness event for Susan G. Komen® Central and ... the Cure provides supporters of all ages an opportunity to ... in. , “Moving the Race to Cesar Chavez Plaza ...
(Date:9/22/2014)... Mich. Many parents whose kids participate in athletics ... education, but that,s not enough to ensure parents are ... University of Michigan C.S. Mott Children,s Hospital National Poll ... of the 912 parents of middle and high school ... education: , , 23% have read a brochure ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
(Date:9/22/2014)... to laser weapons, the Office of Naval Research (ONR) ... Modern Day Marine exposition that will prepare Marines as ... , ONR program officers will be in Booth No. ... Corps Base Quantico, to discuss how their research contributes ... "fast, austere and lethal." , ONR,s Expeditionary Maneuver Warfare ...
Breaking Medicine News(10 mins):Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Some concussion education more useful than others, parents say 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3Health News:Modern Day Marine: ONR features technology for marines of the future 2
... causes epileptic seizures, but researchers from Melbournes Howard Florey ... with the help of their newly developed genetically modified ... mutation based mouse model in the world that mimics ... Dr Steven Petrou and his team to understand the ...
... the University of Pennsylvania School of Medicine have found ... the prognosis of patients with head and neck cancers. ... of CANCER. , The belief that a patients psychological ... cancer is one that has been prominent among patients ...
... upbeat, less positive patients , , MONDAY, Oct. 22 (HealthDay ... how long a person with cancer will survive, a ... that among head and neck cancer patients, emotional health ... factor affecting prognosis. , "We anticipated finding that emotional ...
... Sold Exclusively by GE Healthcare Expands Company ... Offerings within Worldwide Hospital Market, ... CSCX ), a global leader in advanced cardiac monitoring,and ... and has begun full shipments of its new "crash ...
... a prescription NSAID (non-steroidal anti- inflammatory drug) treatment that can be applied directly to ... osteoarthritis pain ... in both the knees and the joints ... of the hands * Offers highly effective ...
... and Item finalize settlement agreement with Teva, ... 22 Astellas,Pharma Inc. ("Astellas"; headquarters: Tokyo; ... ("King"; NYSE: KG) and Teva,Pharmaceutical Industries Ltd. ... of Astellas, along with Item Development AB ...
Cached Medicine News:Health News:Childhood epilepsy research offers new hope for seizure control 2Health News:Penn researchers find emotional well-being has no influence on cancer survival 2Health News:Emotional State Doesn't Affect Cancer Survival 2Health News:Emotional State Doesn't Affect Cancer Survival 3Health News:Emotional State Doesn't Affect Cancer Survival 4Health News:Emotional State Doesn't Affect Cancer Survival 5Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 2Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Adenoscan(R) Patent Lawsuits Settled 2Health News:Adenoscan(R) Patent Lawsuits Settled 3Health News:Adenoscan(R) Patent Lawsuits Settled 4
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
Medicine Products: